Schneede P, Schlenker B
Urologische Klinik, Klinikum Memmingen, Bismarckstraße 23, 87700, Memmingen, Deutschland.
Klinikum der Universität München, Großhadern, München, Deutschland.
Urologe A. 2018 Apr;57(4):413-417. doi: 10.1007/s00120-018-0597-3.
Two major pathways of penile carcinogenesis are known: human papillomavirus (HPV)-induced penile cancer and HPV-negative cancers associated with chronic dermatoses. Therefore, modern measures for prevention of penile cancer may for example include prophylactic HPV vaccination. The resulting B‑cell-mediated immunity to HPV capsid proteins is effective protection against future HPV infections. Contrarily when treating existing HPV infections or HPV-associated cancers an antigen-specific T‑cell immunity is necessary. To date, screening and treatment of precancerous lesions to prevent penile cancer are not established in the German health care program and the highly expected therapeutic HPV vaccines are still on the horizon. In this article, we focus on possible strategies to prevent HPV-related penile cancer on different levels of carcinogenesis.
人乳头瘤病毒（HPV）诱发的阴茎癌和与慢性皮肤病相关的HPV阴性癌症。因此，预防阴茎癌的现代措施例如可能包括预防性HPV疫苗接种。由此产生的针对HPV衣壳蛋白的B细胞介导免疫是预防未来HPV感染的有效保护。相反，在治疗现有的HPV感染或HPV相关癌症时，抗原特异性T细胞免疫是必要的。迄今为止，德国医疗保健计划中尚未确立对癌前病变进行筛查和治疗以预防阴茎癌，备受期待的治疗性HPV疫苗仍未出现。在本文中，我们聚焦于在致癌作用的不同层面预防HPV相关阴茎癌的可能策略。
